REGENERON PHARMACEUTICALS, INC. Treasury Stock, Common, Value
REGENERON PHARMACEUTICALS, INC. (REGN) had Treasury Stock, Common, Value of $20.57 billion as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:TreasuryStockCommonValue · last filed 2026-07-30
- 2026-06-30: Treasury Stock, Common, Value $20.57B.
- 2026-03-31: Treasury Stock, Common, Value $19.41B.
- 2025-12-31: Treasury Stock, Common, Value $18.61B.
- 2025-09-30: Treasury Stock, Common, Value $17.94B.
| Period end | Treasury Stock, Common, Value |
|---|---|
| 2026-06-30 | $20.57B 10-Q · filed 2026-07-30 |
| 2026-03-31 | $19.41B 10-Q · filed 2026-04-29 |
| 2025-12-31 | $18.61B 10-Q · filed 2026-07-30 |
| 2025-09-30 | $17.94B 10-Q · filed 2025-10-28 |
| 2025-06-30 | $17.28B 10-Q · filed 2025-08-01 |
| 2025-03-31 | $16.22B 10-Q · filed 2025-04-29 |
| 2024-12-31 | $15.17B 10-K · filed 2026-02-04 |
| 2024-09-30 | $14.19B 10-Q · filed 2024-10-31 |
| 2024-06-30 | $13.46B 10-Q · filed 2024-08-01 |
| 2024-03-31 | $12.86B 10-Q · filed 2024-05-02 |
| 2023-12-31 | $12.56B 10-K · filed 2025-02-05 |
| 2023-09-30 | $12.27B 10-Q · filed 2023-11-02 |
| 2023-06-30 | $11.77B 10-Q · filed 2023-08-03 |
| 2023-03-31 | $11.05B 10-Q · filed 2023-05-04 |
| 2022-12-31 | $10.35B 10-K · filed 2024-02-05 |
| 2021-12-31 | $8.26B 10-K · filed 2023-02-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |